Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo.
about
Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advancesOncolytic adenovirus-mediated therapy for prostate cancerAdenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-regionOncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?Replication and virus-induced transcriptome of HAdV-5 in normal host cells versus cancer cells--differences of relevance for adenoviral oncolysis.2-aminopurine enhances the oncolytic activity of an E1b-deleted adenovirus in hepatocellular carcinoma cells.Armoring CRAds with p21/Waf-1 shRNAs: the next generation of oncolytic adenoviruses.Oncolytic virotherapy for pancreatic cancer.A vesicular stomatitis virus glycoprotein epitope-incorporated oncolytic adenovirus overcomes CAR-dependency and shows markedly enhanced cancer cell killing and suppression of tumor growth.Novel therapies for pancreatic cancer: setbacks and progressDown-regulation of multiple cell survival proteins in head and neck cancer cells by an apoptogenic mutant of adenovirus type 5.Recent advances in oncolytic virus design.Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets.Pancreatic cancer gene therapy: from molecular targets to delivery systems.Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses.Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials.AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-κB mediated uPAR activation.The combination of i-leader truncation and gemcitabine improves oncolytic adenovirus efficacy in an immunocompetent model.Oncolytic viral therapy for pancreatic cancer.The oncolytic adenovirus AdΔΔ enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models.An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers.Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus GLV-1h68 with nab-Paclitaxel Plus Gemcitabine.The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate CancerSynergistic and Selective Cancer Cell Killing Mediated by the Oncolytic Adenoviral Mutant AdΔΔ and Dietary Phytochemicals in Prostate Cancer Models.Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad∆∆ through Bcl-2-dependent attenuation of autophagy.Role of Gene Therapy in Pancreatic Cancer-A Review.A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer.Combination of interferon-expressing oncolytic adenovirus with chemotherapy and radiation is highly synergistic in hamster model of pancreatic cancer.
P2860
Q26863779-8761AFD3-6C9F-4103-A41A-3DA8A2A1CEABQ27004796-79039CE5-6327-44CF-8248-E70BBCCD011EQ28484203-E585910F-9B4E-42A9-9270-DFB9341E80E8Q33995471-4DE9B315-278A-4EBF-91D2-32C5DE150A2AQ34091152-B1AA3E71-82CF-4DD0-9841-02D12A0817DFQ34764233-8D47785E-1953-4302-8B01-175BAFC1255CQ34992785-BAAB9BF1-1657-4B03-8E31-11A63D7855DBQ35590996-9595CF84-0BC0-4C29-B529-D96938AFFCB9Q36544244-5C6EDD4D-D15F-4BB6-ADB6-BDB73F36A6AEQ37107622-3A0BF0A8-4FED-479E-9F64-81D5FA79DAE3Q37414129-B3307BDC-BA17-4668-9F1E-3DDCED0841D1Q37865172-CF7CA77B-0F06-4FC0-8D3D-20259C2B84ABQ37899223-2B4D8B1D-E570-45CE-8D7D-52714A0A2B03Q38033591-1517CE6D-F942-469B-A1CC-6CE8C69A549EQ38161331-0727C1F5-E6D2-40E6-AF93-29B6C772DEFCQ38237657-6B8AA1C8-452A-4F0C-A8A2-00D208F235AEQ38645375-1332D83E-79A1-4A21-BE5E-D015EB7ACAA8Q38847702-8FA27EF7-3D2E-4DA0-AE85-7E6BDC04B04EQ39033731-8D72C119-556A-4EF7-B0CB-679F8327D4D5Q39240683-51374AB2-FA2E-4347-8FD8-C74BEB1E6BAAQ39462851-0AAB8912-304C-4E94-A2A3-95F9086B1525Q39491356-B473B771-7015-4ED1-9E7E-F5253B508594Q39752863-D57B9FFD-6361-4040-B61A-94DE6CC85452Q40162348-2DAE9303-51BF-4EC3-8922-E4DAC1071BEAQ40913003-932C09DF-4AC3-4663-8FF6-C33BD1BFE953Q41699675-76F1BBE9-57B2-477C-87E6-7FE5C6340896Q42155591-95A965C0-6D92-48A2-B0EF-5AAA133058FDQ47549552-595737DC-D4EF-46E5-9CCB-431003078472Q52610258-4160DC99-A6C3-4969-BB9E-86748462E984Q54975352-E2C42AE5-6F24-4F8F-958E-4A90CB623D3EQ55004955-EB38F4AC-6896-49D3-BAD0-2789F24093DF
P2860
Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Oncolytic adenoviral mutants w ...... d anti-tumor efficacy in vivo.
@en
Oncolytic adenoviral mutants w ...... d anti-tumor efficacy in vivo.
@nl
type
label
Oncolytic adenoviral mutants w ...... d anti-tumor efficacy in vivo.
@en
Oncolytic adenoviral mutants w ...... d anti-tumor efficacy in vivo.
@nl
prefLabel
Oncolytic adenoviral mutants w ...... d anti-tumor efficacy in vivo.
@en
Oncolytic adenoviral mutants w ...... d anti-tumor efficacy in vivo.
@nl
P2093
P2860
P1476
Oncolytic adenoviral mutants w ...... d anti-tumor efficacy in vivo.
@en
P2093
Daniel Oberg
Derek Davies
Enrique Miranda
Gunnel Halldén
Katrina Sweeney
Nick R Lemoine
Stephan Leitner
P2860
P304
P356
10.1158/1078-0432.CCR-08-2008
P407
P577
2009-02-17T00:00:00Z